The syntheses of certain analogues of the DNA minor groove binding agent Hoechst 33258 designed to explore the potential for bioreductive activation and as selective inhibitors of human tumor helicases are described. The structural modifications include the following: substitution of pyridine for benzene ring of the piperazinvl benzimidazole moiety and replacement of one benzimidazole unit by a imidazoquinone moiety.
Introduction
The design of DNA sequence-specific binding agents has received considerable attention because of their potential as anticancer drugs. The synthetic bis-benzimidazole Hoechst dye 33258 is known to bind to the minor groove of double helical DNA selectively at 5' AATT sites (1). The interaction of Hoechst 33258 with DNA has been extensively studied by biophysical methods including footprinting, NMR and X-ray techniques (2).Structural data on Hoechst 33258-DNA complexes from X-ray crystallography (3, 4) and NMR studies (5-7 ) provide evidence for minor groove binding. The flexible nature of the bis-benzimidazole ring system permits the drug to adopt an optimum conformation and thus bind effectively to double stranded DNA (8).
In addition, the quinone class of bioreductive alkylating agents has received increasing attention because of their potential role in cancer therapy. Certain quinones are able to act as bioreductively activated alkylating agents (9). Mitomycin C, a naturally occurring antitumor antibiotic, and the corresponding mitosene analogues bearing a para-quinone moiety, are capable of bioreductive activation to generate reactive quinone methides that alkylate biomolecules (10). Recently, the benzimidazole ring system has been designed as a reductive alkylator by functionalizing the quinone derivative of the ring system with -CH2X, where X is a leaving group (11). These latter types of Synthesis of Hoechst 33258 Analogues designed to target human tumor helicases quinone derivatives result in quinone methide formation upon quinone reduction (11) and this suggests that if we incorporate a quinone methide precursor into the Hoechst 33258 structure it should be effective both as a sequence and site directed groove binder as well as selective alkylator.
Several indole quinones have recently been studied as bioreductive drugs (12). These studies aroused our interest in this area and the synthetic and biological studies of prototypes of such analogues of Hoechst 3325S bearing a quinone moiety have been reported including their property of sequence selective inhibition of human tumor helicases (13) (14) (15) .
Indolqulnone ring system
Benzimidazolequinone ring system
As part of our ongoing research on the synthesis of Hoechst 33258 with structural modifications we report on agents consisting of substitution of the benzene ring by pyridine in one of the benzimidazole moieties so as to change the sequence recognition within the minor groove in a predictable manner, and with replacement of another benzimidazole unit by an imidazoquinone moiety
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in order to examine synthetically the effect of the structural changes on both biophysical and pharmacological properties, especially their property of inhibiting human tumor helicases (14, 15) .
Results and Discussion
The present target molecules were obtained by a convergent approach outlined in the Scheme. 2-Methoxymethyl-l-methyl-4,7-dimethoxy benzimidazole 1 and its formylated product 2 was obtained by a reported procedure (13) . Compound 3 was obtained as reported (16) using nitrobenzene mediated coupling of the appropriate orthodiamine and aldehyde (17) . Demethylation of containing an electron donor element is present in the molecule (18) . For the reaction compound 3
and BBr3 a molar ratio of 1:9 was used to afford a completely demethylated product 4. The hydroquinone 4 thus obtained was subjected to oxidation using ρ -chloranil in methanol. Oxidations using CAN and Ag20 were also attempted but were not successful. The reaction with /?-chloranil however proceeds smoothly at room temperature. Upon oxidation of 4, two products 5 and 6 were obtained as shown in the scheme, that were isolated by column chromatography on silica gel using CHCl3-MeOH as eluent. Compound 6, as expected, proved to be a racemic mixture and the specific rotation is zero within experimental limits. Although the structure of compound 6 has not been definitively established, the NMR and mass data support the structure depicted in the scheme above.
Detailed structural and mechanistic studies have yet to be performed on compound 6. Treatment of 5 with PCI5 in DMF gave the compound 7 (13).Biophysical and pharmacological evaluation of the new agents is underway and will be reported in due course. 
5-(4-Methy 1-1-piperazinyl)-2-[2*-(hydroxy methyl)-l'-methy 1-4\7'-dihydroxybenzimidazo-5'-yl]-3H-imidazo[4,5b]pyridine (4)
Compound 4 was obtained by the reported procedure (19) with some modification. Compound 3 (90.2mg) was dissolved in freshly distilled CH2 Cl2 (40 ml) and cooled to -78 °C, then to it BB13
(500 mg) in dry CH2 CI2 (20 ml) was slowly added and the mixture was allowed to reach to room The title compounds were obtained by applying the reported procedure (13) . To a solution of 4 (40.9 mg, 0.1 mmol) in anhydrous MeOH (50 ml) was added /vchloranil (105 mg, 0.5 mmol) and the resulting mixture was stirred for 2 hrs before concentrating in vacuum.Both the products were isolated by column chromatography on silica gel. Elution with CHCI3 -MeOH (7:3) gave 5 (15 mg) and further elution with CHCl3-MeOH(5:5) gave 6 (16 mg) as dark purple solid. 
